ArticleFrontiers in endocrinology2026
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We investigated the role of SIRT1 in linear growth and bone structure, focusing on the response of the epiphyseal growth plate (EGP) to nutritional manipulation. Methods: A ColX-Cre driver was used to target hypertrophic chondrocytes (HZ), and generate hypertrophic specific Sirt1 knockout (CKO) mice. Results: We found that Sirt1 deletion in hypertrophic chondrocytes markedly impaired growth in males, with a 33% reduction in body weight and 10-11% shorter long bones and EGP height (P<0.05). In females, effects were milder (12% reduction in weight, 5-7% shorter long bones; P<0.05 in both) but EGP height was reduced similarly to the males. These mice were next tested in a catch-up (CU) growth model involving food restriction followed by refeeding. Under CU conditions, male CKO mice showed an unexpected exaggerated response, surpassing the weight and bone length of normally fed CKO. Discussion: We therefore conclude that targeted Sirt1 deletion in the hypertrophic zone revealed a strong sex-dependent effect on skeletal growth and bone quality. Both male and female CKO mice exhibited growth impairment under normal conditions compared to littermate control (CTL), however while male showed hyper-responsiveness to refeeding, females CKO showed only moderate alterations. This targeted approach uncovers sex-dependent role for SIRT1 in regulating growth and bone quality, moving beyond its generally understood functions in cartilage and bone development. The distinct responses to both basal conditions and nutritional stress between sexes represent a significant new finding, extending its known role beyond general cartilage and bone development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.